IL-2 treatment in combination with rapamycin has been shown to mitigate acute GVHD lethality, which is associated with increased expansion of donor-type CD4+Foxp3+ Treg cells and reduction of CD4+CD25− conventional T cells [67]. This evidence concerns the gene FOXP3 and graft versus host disease.